- Core Services
- Medical Tourism
Medical tourism refers to the movement of a patient from a highly developed nation to avail cost effective yet world class medical treatment at affordable costs,which are otherwise very expensive in their own country.
- Wellness Tourism
- Corporate Alliance
- About Us
- Contact Us
This email address is being protected from spambots. You need JavaScript enabled to view it.
Treatments
- Dental Treatments
- Cosmetic Surgeries
- Orthopaedics
- Oncology/Cancer Treatment
- Cardiac Care/Heart Treatment (adult and pediatric)
- Bariatric/Obesity Treatment
- Opthalmology/Eye Care
- NeuroSurgery
- Heart/Lung/Bone MarrowTransplants
- Renal Care / Urology
- Gynaecology
- IVF/Infertility/Test Tube/Surrogacy
- ENT/Otolaryngology
- Gastroenterology
- Spinal Surgery
- Stem Cell Treatment
- Plastic and Reconstructive Surgery
- 28 May, 2016India Grants Patent for Gilead’s Hepatitis C DrugUS pharmaceutical giant Gilead has obtained a patent for its Hepatitis C drug from India. This patent could potentially stop affordable copies reaching millions of people in other countries. The drug, Sovaldi, which costs $1,000 a pill in the United States, was rejected for a patent in January 2015 following opposition by health activists who said the science was not sufficiently new.
- 24 May, 2016Indian Healthcare sector poised to grow to $280 bn: ReportIndian healthcare sector is poised to grow to $280 billion by 2020 while it is expected to be a leader in e-health by 2019, a new report said today. The CII-KPMG, The Indian services sector: Poised for global ascendancy: report launched at the second edition of Global Exhibition on Services (GES) said that healthcare sector is forecast to reach $160 billion in 2017, accounting for about 4.2 per cent of GDP. India\'s healthcare sector poised to grow to $280 bn: Report
- 13 May, 2016Hepatitis C Drug to be Offered Soon in India at Only One Percent of Its Cost in USAPatent holder and pharma major Gilead, announced voluntary licences with seven generic drug manufacturers in India to sell lower-cost versions of a $1,000-a-pill for hepatitis C treatment in poorer countries. Cadila Healthcare, Cipla, Hetero Labs, Mylan Laboratories, Ranbaxy Laboratories, Sequent Scientific and Strides Arcolab, under the licensing agreement have the right to develop and market generic versions of sofosbuvir in 91 developing countries. However Indian manufacturers will not be ...
- 24 April, 2016Fortis La Femme, Breast Milk Bank Foundation to launch Delhi-NCR\'s first human milk bankFortis La Femme in association with the Breast Milk Bank Foundation will launch the Delhi-NCR\'s first human milk bank on April 26. This joint initiative milk bank has been called as \"Amaara\", and will be formally launched at 11.30 a.m. on Tuesday. Mr. Bhavdeep Singh, CEO of Fortis Healthcare will attend the inauguration, which will be followed by a press conference.
- 17 April, 2016Surgery in India Helps Nigerian Woman Stand Up on Her Feet After 11 YearsA 65-year old Nigerian woman, crippled for 11 years due to chronic rheumatoid arthritis, is now back on her feet, thanks to a life-changing surgery she underwent in India. Margaret was bedridden for 11 years and had almost lost hope of being able to walk again.
Latest News
02 March 2017
Sex-Change Surgery: India\'s New Line In Budget Medical Tourism
After decades of battling depression, former soldier Betty Ann Archer finally flew to New Delhi to complete her gender transition, one of a growing number of foreigners heading to India for budget sex-change operations. Born Dale Archer, the 64-year-old American said she felt trapped in the wrong body right from the start, recalling secretly trying on her mother\'s dresses as a boy -- much to the horror of her conservative military father. \"I attempted to kill myself twice...
Our Associations
© 2013 Copyright, Rejuvindiameditour. All rights reserved.